Clinical Trial of Cell Therapy for Stroke Disability
Author: SanBio Inc
Synopsis and Key Points:
Phase 1/2a clinical trial testing safety and efficacy of allogeneic cell therapy product SB623 on patients suffering from stable deficits resulting from previous stroke injuries.
Main DigestStanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability.
The Stanford University School of Medicine and SanBio Inc. today announced the initiation of a Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, on patients suffering from stable deficits resulting from previous stroke injuries. For details regarding this clinical trial, please refer to the Clinicaltials.gov website www.clinicaltrials.gov/ct2/show/NCT01287936.
SB623 is derived from adult bone marrow and has shown safety and efficacy in rodent models of stroke disability. "SB623 represents a significant step forward in the development of regenerative therapies for the treatment of brain injury," said Keita Mori, SanBio CEO. "We are pleased to initiate a first-in-man study of SB623."
SB623 will be administered by intracranial injection into the damaged region of the brains of patients who have suffered an ischemic stroke. Product safety is the primary focus of the study but various measurements of efficacy will also be tested.
"This is a completely new approach to therapy for stroke victims," said Dr. Gary Steinberg, the Lacroute-Hearst Professor, Chairman of the Department of Neurosurgery, and Director of the Stanford Institute for Neuro-Innovation and Translational Neurosciences at the Stanford University School of Medicine, and Principal Investigator of the study. Sub-Investigator Dr. Neil Schwartz, Clinical Assistant Professor of Neurology, Stanford Stroke Center, said, "If successful, this cell therapy offers hope to otherwise permanently disabled patients."
About SB623: SB623 is a proprietary regenerative cell therapy consisting of cells derived from genetically engineered bone marrow stromal cells obtained from healthy adult donors. SB623 is implanted directly adjacent to the area damaged by stroke and functions by producing proteins that aid the healing process.
About SanBio: SanBio is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of new regenerative cell therapy products.
About Stanford: Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics, and Lucile Packard Children's Hospital. For more information, please visit the Office of Communication & Public Affairs site at mednews.stanford.edu/.
For more information: www.san-bio.com
- 1 - New Multiple Sclerosis Treatment Clinical Trial Begins Enrollment : The Immune Tolerance Network; Benaroya Research Institute at Virginia Mason. (2020/01/07)
- 2 - Pediatric Neural Tumor Shrinkage Shown in Selumetinib Clinical Trial : NIH/National Cancer Institute (2016/12/29)
- 3 - Clinical Trial Recognizes Needs of Severely Disabled MS Patients : Queen Mary University of London (2018/06/16)
- 4 - Largest Autism Clinical Trial in History Extends Recruitment Target : IMAGIRATION, LLC (2016/06/15)
- 5 - Intensity Therapeutics Human Cancer Clinical Trial Update : Intensity Therapeutics, Inc. (2018/03/26)
- 6 - Fighting My Cancer as Much as Possible - Why Many Patients Join Phase 1 Clinical Trials : European Society for Medical Oncology (2018/03/23)
- 7 - Groundbreaking Autism Clinical Trial Regarding Cord Blood Stem Cells : Sutter Neuroscience Institute (2012/08/25)
• Disabled World is strictly a news and information website provided for general informational purpose only and does not constitute medical advice. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World.